PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
Journal of Clinical Medicine · 16.11.2023 · 12 (22) · 7130
DOI: 10.3390/jcm12227130 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.11.2023. Verfasst von Luca Urso und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine-PET/CT Center, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently incorporated into international guidelines for several different indications in prostate cancer (PCa) patients. However, there are still some open questions regarding the role of PSMA ligand PET in castration-resistant prostate cancer (CRPC). The aim of this work is to assess the clinical value of PSMA ligand PET/CT in patients with CRPC. Results: PSMA ligand PET has demonstrated higher detection rates in comparison to conventional imaging and allows for a significant reduction in the number of M0 CRPC patients. However, its real impact on patients’ prognosis is still an open question. Moreover, in CRPC patients, PSMA ligand PET presents some sensitivity and specificity limitations. Due to its heterogeneity, CRPC may present a mosaic of neoplastic clones, some of which could be PSMA−/FDG+, or vice versa. Likewise, unspecific bone uptake (UBU) and second primary neoplasms (SNPs) overexpressing PSMA in the neoangiogenic vessels represent potential specificity issues. Integrated multi-tracer imaging (PSMA ligand and [18F]FDG PET) together with a multidisciplinary discussion could allow for reaching the most accurate evaluation of each patient from a precision medicine point of view.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nuclear Medicine-PET/CT Center, S. Maria della Misericordia Hospital, 45100 Rovigo, Italy.
- Nuclear Medicine Unit, Department of Oncohaematology, Fondazione PTV, Policlinico Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy.
- Nuclear Medicine Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy.
- Nuclear Medicine Unit, Onco-Hematological Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
- Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Milan, Italy.
ORCID-Profile: Luca Urso, Luca Filippi, Corrado Cittanti, Luigia Florimonte, Massimo Castellani, Paolo Zucali, Alessio Bruni, Roberto Sabbatini, Stefano Panareo, Laura Evangelista
Zitieren
APA
Urso, L., Filippi, L., Castello, A., Marzola, M. C., Bartolomei, M., Cittanti, C., Florimonte, L., Castellani, M., Zucali, P., Bruni, A., Sabbatini, R., Dominici, M., Panareo, S., & Evangelista, L. (2023). PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?. Journal of Clinical Medicine, 12(22), 7130. https://doi.org/10.3390/jcm12227130
Vancouver
Urso L, Filippi L, Castello A, Marzola MC, Bartolomei M, Cittanti C, et al. PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?. Journal of Clinical Medicine. 2023;12(22):7130. doi:10.3390/jcm12227130
BibTeX
@article{Urso2023,
author = {Urso, Luca and Filippi, Luca and Castello, Angelo and Marzola, Maria Cristina and Bartolomei, Mirco and Cittanti, Corrado and Florimonte, Luigia and Castellani, Massimo and Zucali, Paolo and Bruni, Alessio and Sabbatini, Roberto and Dominici, Massimo and Panareo, Stefano and Evangelista, Laura},
title = {PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {22},
pages = {7130},
doi = {10.3390/jcm12227130}
}
EUVIMED